CollPlant is a clinical-stage regenerative medicine company focused on developing and commercializing tissue repair products, initially for the orthobiologics and advanced wound care markets. Our products, two of which are in registration trials, are based on our proprietary plant-based collagen technology, which we believe is the only viable technology available for the production of recombinant type I human collagen. We believe that our rhCollagen, which is identical to the type I collagen produced by the human body, has significant advantages compared to currently marketed tissue-derived collagen. The attributes of our rhCollagen make it suitable for numerous tissue repair applications throughout the human body. We believe that the market opportunity for our current products utilizing our rhCollagen within the orthobiologics and advanced wound care markets exceeds $5 billion.
Collplant is a public company listed on the Tel Aviv Stock Exchange and on the OTCQX